Thus, a combination of multiple biomarkers could be helpful, as demonstrated by the increased performance using a combination of PD-L1 immunohistochemistry, T-cell infiltration, and assessment of tumor mutational burden when compared with the three parameters alone [21]. This evidence concerns the gene CD274 and neoplasm.